Tadalafil vs Tadalafil Peptide
A side-by-side research comparison of Tadalafil and Tadalafil Peptide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Tadalafil | Tadalafil Peptide |
|---|---|---|
| Full name | Tadalafil (Cialis) | Tadalafil-Peptide Conjugate (Experimental) |
| Category | Sexual Health | Sexual Health |
| Status | FDA-approved prescription | Research compound |
| Mechanism | Selectively inhibits phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in smooth muscle. This enhances nitric oxide signaling for vasodilation in penile, pulmonary, and prostate tissue. | CPP moiety facilitates targeted PDE5 inhibitor delivery to penile smooth muscle. Local PDE5 inhibition increases cGMP for NO-mediated vasodilation with reduced systemic exposure. |
| Molecular weight | 389.40 Da | ~2,500 Da (conjugate) |
| Half-life | ~17.5 hours | 8-12 hours |
| Bioavailability | ~36% oral | Targeted (topical/local) |
| Typical dose | 2.5-5 mg daily or 10-20 mg as needed | 1-5 mg equivalent |
| Frequency | Daily or on-demand | As needed |
| Route | Oral tablet | Topical or local injection |
Tadalafil reported benefits
- Erectile function improvement
- Cardiovascular health (vasodilation)
- Prostate health (BPH)
- Improved exercise capacity
- Nitric oxide support
Tadalafil Peptide reported benefits
- Targeted PDE5 inhibition
- Reduced systemic side effects
- Potentially faster onset
- Lower dose requirement
Related comparisons
Research and educational reference only. Not medical advice.